19 June 2017
WE ARE PLEASED TO ANNOUNCE THE BEGINNING OF PHASE 2/3 OF OUR ACTIVE TARGETED IMMUNOTHERAPY FOR MYASTHENIA GRAVIS following the approval by the UZA Ethics Committee on 19 June 2017 and the Belgian and Dutch Regulatory Authorities (May 2017)
19-22 June 2017
Thank you for visiting us Bio 2017 in San Diego on the Belgian Booth and/or meeting us thru One-on-One Partnering
15-17 May 2017
THE PRELIMINARY RESULTS OF THE ONGOING PHASE 1B CLINICAL TRIAL ON PATIENTS OF CV-MG01 VS. PLACEBO DEMONSTRATE SAFETY AND INDICATE EFFICACY AS COMMUNICATED AT THE 13TH INTERNATIONAL CONFERENCE ON MYASTHENIA GRAVIS AND RELATED DISORDERS AT THE NEW YORK ACADEMY OF SCIENCE ON 16 MAY 2017
7-9 November 2016
Thank you vor visiting us at Bio Europe 2016 in Köln
5-9 June 2016
Thank you for visiting us at Bio 2016 in San Francisco
2-4 November 2015
Thank you for meeting us at Bio Europe 2015 in Munich
CuraVac’s MG therapeutic vaccine receives Clinical Trial Authorization (CTA) in Belgium and the Ethical Committee of the University Hospital of Antwerp (UZA) gives its authorization for a Phase 1b trial on 32 patients.
15-19 June 2015
Thank you for meeting us at Bio 2015 in Philadelphia.
10 December 2014
3-5 November 2014
Thank you for meeting us at Bio Europe 2014 in Frankfurt
9 October 2014
23-26 June 2014
Thank you for visiting us at Bio 2014 in San Diego on the Belgian Pavilion
6 June 2014
CURAVAC AND THE MYASTERIX PROJECT WON THE AWARD OF THE BEST IMMUNOTHERAPIES & VACCINES PROJECT AT BIOVISION 2014 (June 2014)
CuraVac will present the company and the myasterix project at BioVision on June 6th in Lyon, France
CuraVac was present at Buzz4Bio
CuraVac is proud to announce the start of the Myasterix project.
An independent Jury deems the Myasterix project one of the seven best therapeutic vaccine projects and recommends that the European Commission subsidizes the project.
CuraVac attends the Bio 2013 convention in Chicago
CuraVac creates the Myasterix consortium
CuraVac attends the Bio 2012 convention in Boston